Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | MARK3 | P27448 | 1/20 | 0.45 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.45 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29504836 | 1.00 | L3MBTL1 (0.67) | L3MBTL1EPHX1PDE10AHTR6ADAM17 | |
| SCHEMBL30859622 | 0.89 | L3MBTL1 (0.65) | L3MBTL1EPHX1PDE10AHTR6ADAM17 | |
| SCHEMBL4892277 | 0.89 | L3MBTL1 (0.65) | L3MBTL1EPHX1PDE10AHTR6ADAM17 | |
| SCHEMBL10088115 | 0.89 | L3MBTL1 (0.74) | L3MBTL1EPHX1PDE10AHTR6ADAM17 | |
| SCHEMBL1520892 | 0.89 | L3MBTL1 (0.70) | L3MBTL1EPHX1PDE10AHTR6ADAM17 | |
| SCHEMBL5740514 | 0.86 | L3MBTL1 (0.65) | L3MBTL1EPHX1PDE10AHTR6ADAM17 | |
| SCHEMBL13109139 | 0.86 | L3MBTL1 (0.65) | L3MBTL1EPHX1PDE10AHTR6ADAM17 | |
| SCHEMBL23522089 | 0.86 | L3MBTL1 (0.67) | L3MBTL1EPHX1PDE10AHTR6ADAM17 | |
| SCHEMBL22153097 | 0.86 | L3MBTL1 (0.67) | L3MBTL1EPHX1PDE10AHTR6ADAM17 | |
| SCHEMBL25911437 | 0.86 | L3MBTL1 (0.67) | L3MBTL1EPHX1PDE10AHTR6ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-115959962-B | Visible light-promoted halogenated alkane hydrodehalogenation method | 中国科学院兰州化学物理研究所 | 2025-05-23 | — | — | CN | disclosed |
| WO-2024258728-A2 | EPIDITHIODIKETOPIPERAZINE ANALOGS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240409542-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-12-12 | — | — | US | disclosed |
| CN-118139864-A | New compounds | 西特瑞治疗有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-11999716-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2023-12-21 | — | — | US | disclosed |
| CN-115959962-A | Visible light promoted halogenated alkane hydrodehalogenation method | 中国科学院兰州化学物理研究所 | 2023-04-14 | — | — | CN | disclosed |
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-12 | — | — | US | disclosed |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-5859007-A | TREATMENT OF DIABETES, OBESITY | GLAXO WELLCOME INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5801248-A | Stereoselective syntheses | OXFORD ASYMMETRY INTERNATIONAL PLC. (GB) | 1998-09-01 | — | — | US | disclosed |
| US-5795887-A | Method of inducing cholecystokinin agonist activity using 1,4- Benzodiazepine compounds | GLAXO WELLCOME INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0755384-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0755394-A1 | A METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS | GLAXO WELLCOME INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| US-5554753-A | Catalytic enantioselective synthesis of α-amino acid derivatives by phase-transfer catalysis | INDIANA UNIVERSITY FOUNDATION (US) | 1996-09-10 | — | — | US | disclosed |
| WO-1995028399-A1 | A METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1995028391-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1995006029-A1 | ENANTIOSELECTIVE SYNTHESIS OF ALPHA - ALKYLATED AMINO ACID DERIVATIVES BY PHASE - TRANSFER CATALYSIS | INDIANA UNIVERSITY FOUNDATION (US) | 1995-03-02 | — | — | WO | disclosed |
| US-5173496-A | Antiinflammatory agents | ICI PHARMA (FR) | 1992-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | L3MBTL1 782/4885EPHX1 3467/4885PDE10A 3800/4885 |
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR77 | L3MBTL1 1089/4885EPHX1 2547/4885PDE10A 4355/4885 |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | L3MBTL1 782/4885EPHX1 3467/4885PDE10A 3800/4885 |
| US-11999716-B2 | WDR5 inhibitors and modulators | WDR5, WDR1, WDR3 | L3MBTL1 1118/4885EPHX1 2637/4885PDE10A 4283/4885 |
| US-20240409542-A1 | NOVEL COMPOUNDS | CD47, GPR119, LRBA | L3MBTL1 3300/4885EPHX1 714/4885PDE10A 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.